Logos Capital is a San Francisco healthcare investment firm that backs biotech companies from private rounds through their public life, and turns up repeatedly in cancer drug financings.
Logos Capital is a healthcare-focused investment firm based in San Francisco with offices in San Diego and Boston, investing in private and public biotechnology companies with a data-driven, clinically grounded approach. It appears as a participant in several of the sourced oncology rounds in OnCo, typically as part of a syndicate rather than as the company-creating lead. Portfolio links here are derived from the startup records that name it; the firm's own site describes its team and approach rather than listing a full portfolio.
| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Adcendo Copenhagen, DK | Growth stage | biotech | Sarcomas (soft tissue, bone, GIST) | Series C 2026, $75M |
| Obsidian Therapeutics Cambridge, MA, US | Public | cell therapy | MelanomaNon-small-cell lung cancer | Crossover 2026, $350M |
| Tango Therapeutics Boston, MA, US | Public | biotech | Pancreatic ductal adenocarcinomaNon-small-cell lung cancerGlioma & glioblastoma | IPO 2021, $353M |
| Triana Biomedicines Lexington, MA, US | Startup | biotech | Non-small-cell lung cancerHR-positive / HER2-negative breast cancer | Series B 2025, $120M |
Shares Obsidian Therapeutics, Adcendo and the tag vc.
Shares Obsidian Therapeutics, Triana Biomedicines, Adcendo, Tango Therapeutics and the tag vc.
Shares Obsidian Therapeutics, Adcendo and the tag vc.
Shares Obsidian Therapeutics, Triana Biomedicines and the tag vc.
Shares Obsidian Therapeutics, Tango Therapeutics and the tag vc.
Shares Adcendo and the tag vc.
Shares Tango Therapeutics and the tag vc.
Shares Adcendo and the tag vc.